glucagon receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-31 and is reviewed periodically as new material appears.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 per cent or higher by RP-HPLC | Tighter grades reported near 98 per cent |
| Identity confirmation | Mass match by LC-MS | Observed mass compared with sequence-derived mass |
| Storage after dissolution | 2–8 °C, protected from light | Short-term use; avoid repeated freeze–thaw |
| Main degradation routes | Hydrolysis, oxidation, aggregation | Backbone and side-chain susceptibility in solution |
| Common diluents | Sterile water or bacteriostatic water | Choice depends on assay and sterility needs |
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
=== Insulin lispro === Insulin lispro, marketed under the brand name Humalog among others, is a modified form of medical insulin used to treat both type 1 and type 2 diabetes. It is administered subcutaneously through injection or an insulin pump. The effects typically begin within 30 minutes and last for about 5 hours. Sometimes, a longer-acting insulin, such as insulin NPH, is also used. Common side effects include low blood sugar, while more serious side effects may include low blood potassium. It is generally considered safe for use during pregnancy and breastfeeding. It functions similarly to human insulin by increasing glucose uptake in tissues and reducing the amount of glucose produced by the liver in gluconeogenesis. Insulin lispro was first approved for use in the United States in 1996. It is a synthetic analogue of human insulin, created by swapping two amino acids. In 2022, it ranked as the 70th most commonly prescribed medication in the United States, with over 9 million prescriptions. Insulin lispro is available under a generic label from Lilly.
=== Methods for analysis of enantiomers === Methods for measuring the two enantiomers are straightforward and include normal-phase liquid chromatography, liquid chromatography with a chiral column. However, since methods can be used to alter the two enantiomers, it may not be possible to distinguish tobacco-derived from synthetic nicotine simply by measuring the levels of the two enantiomers. A new approach uses hydrogen and deuterium nuclear magnetic resonance to distinguish tobacco-derived and synthetic nicotine based on differences the substrates used in the natural synthetic pathway performed in the tobacco plant and the substrates most used in synthesis. Another approach measures the carbon-14 content which also differs between natural and laboratory-based tobacco. These methods remain to be fully evaluated and validated using a wide range of samples.
=== Notable cases === 1994: Lucien Bouchard, future premier of Québec, Canada, who was infected while leader of the federal official opposition Bloc Québécois party, lost a leg to the illness. 1994: A cluster of cases occurred in Gloucestershire, in the west of England. Of five confirmed and one probable infection, two died. The cases were believed to be connected. The first two had acquired the Streptococcus pyogenes bacteria during surgery; the remaining four were community-acquired. The cases generated much newspaper coverage, with lurid headlines such as "Flesh Eating Bug Ate My Face". 1997: Jeff Moorad, former agent and partial owner of the San Diego Padres and Arizona Diamondbacks, contracted the disease. He had seven surgeries in a little more than a week and later fully recovered. 2004: Don Rickles, American stand-up comedian, actor, and author, known especially for his insult comedy, contracted the disease in his left leg. He had six operations and later recovered. The condition confined him in his later years to performing comedy from a chair. 2004: Eric Allin Cornell, winner of the 2001 Nobel Prize in Physics, lost his left arm and shoulder to the disease. 2005: Alexandru Marin, an experimental particle physicist, professor at MIT, Boston University, and Harvard University, and researcher at CERN and JINR, died from the disease. 2006: Alan Coren, British writer and satirist, announced in his Christmas column for The Times that his long absence as a columnist had been caused by his contracting the disease while on holiday in France. 2009: R. W.
Sources: en.wikipedia.org
The university's dental hospital moved to the Huaxiba campus in 1928 and became the Stomatological Hospital of West China Union University. During the 1930s and 1940s, the institution expanded its research and academic activities. A medical and dental research section was established in 1936, followed by a dedicated oral-disease research section in the 1940s.
The isotope-ratio mass spectrometer (IRMS) allows the precise measurement of mixtures of naturally occurring isotopes. Most instruments used for precise determination of isotope ratios are of the magnetic sector type. This type of analyzer is superior to the quadrupole type in this field of research for two reasons. First, it can be set up for multiple-collector analysis, and second, it gives high-quality 'peak shapes'. Both of these considerations are important for isotope-ratio analysis at very high precision and accuracy. The sector-type instrument designed by Alfred Nier was such an advance in mass spectrometer design that this type of instrument is often called the 'Nier type'. In the most general terms the instrument operates by ionizing the sample of interest, accelerating it over a potential in the kilo-volt range, and separating the resulting stream of ions according to their mass-to-charge ratio (m/z). Beams with lighter ions bend at a smaller radius than beams with heavier ions. The current of each ion beam is then measured using a 'Faraday cup' or multiplier detector. Many radiogenic isotope measurements are made by ionization of a solid source, whereas stable isotope measurements of light elements (e.g. H, C, O) are usually made in an instrument with a gas source. In a "multicollector" instrument, the ion collector typically has an array of Faraday cups, which allows the simultaneous detection of multiple isotopes.
== History == Metribolone was first described in the literature in 1965. It was studied clinically in the late 1960s and early 1970s, most notably in the treatment of advanced breast cancer. The drug was found to be effective and showed weak androgenicity, but also produced severe signs of hepatotoxicity, and was ultimately never marketed. By the mid-1970s, metribolone was becoming an accepted standard as a ligand and agonist of the AR in scientific research. It remains in wide use for this purpose today. Aside from scientific research, metribolone has also been encountered as an AAS in non-medical contexts, for instance in doping in sports and bodybuilding.
All forms of androgen insensitivity, including CAIS, are associated with infertility, though exceptions have been reported for both the mild and partial forms. CAIS is associated with a decreased bone mineral density. Some have hypothesized that the decreased bone mineral density observed in women with CAIS is related to the timing of gonadectomy and inadequate estrogen supplementation. However, recent studies show that bone mineral density is similar whether gonadectomy occurs before or after puberty, and is decreased despite estrogen supplementation, leading some to hypothesize that the deficiency is directly attributable to the role of androgens in bone mineralization. CAIS is also associated with an increased risk for gonadal tumors (e.g. germ cell malignancy) in adulthood if gonadectomy is not performed. The risk of malignant germ cell tumors in women with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. The incidence of gonadal tumors in childhood is thought to be relatively low; a recent review of the medical literature found that only three cases of malignant germ cell tumors in prepubescent girls have been reported in association with CAIS in the last 100 years. Some have estimated the incidence of germ cell malignancy to be as low as 0.8% before puberty. Vaginal hypoplasia, a relatively frequent finding in CAIS and some forms of PAIS, is associated with sexual difficulties including vaginal penetration difficulties and dyspareunia.
Sources: en.wikipedia.org
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.
Mass spectrometry is the standard check, comparing the measured mass with the mass calculated from the published amino acid sequence. Retention time on HPLC and peptide mapping provide supporting evidence. Sequence-level confirmation separates it from closely related analogues.
Dry powder is chemically stable enough for freezer storage over long periods. In solution, water participates directly in hydrolysis and enables aggregation, so breakdown accelerates. Cold, dark, short-term storage after dissolution reflects that difference.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.